NewLink Genetics Phase III study of algenpantucel-L for patients with resected pancreatic cancer failure

10 May 2016

US biopharma NewLink Genetics (Nasdaq: NLNK) has announced that its Phase III trial of of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint.

The company’s shares dropped by 37% in extended trading on Monday after the news was announced that the Immunotherapy for Pancreatic Resectable cancer Study (IMPRESS) had shown no statistical difference for long-term survival.

NewLink Genetics aims to develop and seek approval for multiple product candidates from its HyperAcute Cellular Immunotherapy and IDO/TDO inhibitor platforms for patients with many different cancers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK